DK2726092T3 - Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf - Google Patents

Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2726092T3
DK2726092T3 DK12804863.4T DK12804863T DK2726092T3 DK 2726092 T3 DK2726092 T3 DK 2726092T3 DK 12804863 T DK12804863 T DK 12804863T DK 2726092 T3 DK2726092 T3 DK 2726092T3
Authority
DK
Denmark
Prior art keywords
procedures
fusion polypeptides
serpin fusion
serpin
polypeptides
Prior art date
Application number
DK12804863.4T
Other languages
English (en)
Inventor
Brendan P Eckelman
John C Timmer
Peter L Nguy
Grant B Guenther
Quinn Deveraux
Original Assignee
Inhibrx Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Lp filed Critical Inhibrx Lp
Application granted granted Critical
Publication of DK2726092T3 publication Critical patent/DK2726092T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
DK12804863.4T 2011-06-28 2012-06-28 Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf DK2726092T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161502055P 2011-06-28 2011-06-28
US201161570394P 2011-12-14 2011-12-14
US201161577204P 2011-12-19 2011-12-19
US201261638168P 2012-04-25 2012-04-25
PCT/US2012/044730 WO2013003641A2 (en) 2011-06-28 2012-06-28 Serpin fusion polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
DK2726092T3 true DK2726092T3 (da) 2019-09-30

Family

ID=47424806

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12804863.4T DK2726092T3 (da) 2011-06-28 2012-06-28 Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf

Country Status (27)

Country Link
US (7) US8980266B2 (da)
EP (2) EP3569243A1 (da)
JP (5) JP2014523900A (da)
KR (5) KR102231139B1 (da)
CN (3) CN110066340B (da)
AU (4) AU2012275287B2 (da)
BR (1) BR112013033799A2 (da)
CA (2) CA2839619C (da)
CY (1) CY1122195T1 (da)
DK (1) DK2726092T3 (da)
ES (1) ES2746052T3 (da)
HR (1) HRP20191652T1 (da)
HU (1) HUE046156T2 (da)
IL (3) IL312872A (da)
IN (1) IN2013MN02441A (da)
LT (1) LT2726092T (da)
ME (1) ME03473B (da)
MX (1) MX356517B (da)
NZ (1) NZ744257A (da)
PL (1) PL2726092T3 (da)
PT (1) PT2726092T (da)
RS (1) RS59368B1 (da)
RU (5) RU2698655C2 (da)
SG (2) SG10201601621PA (da)
SI (1) SI2726092T1 (da)
UA (1) UA124083C2 (da)
WO (1) WO2013003641A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200044138A (ko) 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
MX356517B (es) * 2011-06-28 2018-06-01 Inhibrx Llc Polipéptidos de fusión de serpina y métodos de uso de los mismos.
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR20140068861A (ko) * 2011-06-28 2014-06-09 인히브릭스 엘엘씨 Wap 도메인 융합 폴리펩티드 및 이의 이용 방법
JP2015504675A (ja) * 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
KR101509020B1 (ko) * 2013-05-22 2015-04-14 (주)입디 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도
WO2015191892A2 (en) 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES
ES2793051T3 (es) * 2014-07-23 2020-11-12 Inova Diagnostics Inc Composiciones y métodos para el diagnóstico de la artritis reumatoide
WO2016069574A1 (en) * 2014-10-27 2016-05-06 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US11422719B2 (en) * 2016-09-15 2022-08-23 Pure Storage, Inc. Distributed file deletion and truncation
US12031144B2 (en) 2017-03-29 2024-07-09 Cornell University Oxidation-resistant AAT gene therapy
EP3657946B1 (en) 2017-07-27 2024-11-06 The Regents of The University of Michigan Plasminogen activator inhibitor-1 (pai-1) inhibitor and method of use
EP4321220A3 (en) 2017-12-01 2024-03-20 CSL Behring LLC A1at for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
BR112021008200A2 (pt) * 2018-10-29 2021-12-14 Spin Therapeutics Llc Composições e métodos para distúrbios de alfa-1-antitripsina
EP4007751A4 (en) * 2019-08-01 2023-07-05 Serplus Technology LLC OXIDATION RESISTANT SERPINES
CN110964094B (zh) * 2019-12-20 2021-11-02 华中科技大学 人源白细胞蛋白酶抑制因子及其重组制备与应用
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
US20240301381A1 (en) * 2021-01-26 2024-09-12 National Research Council Of Canada Ace2-receptor ectodomain fusion molecules and uses thereof
GB202102258D0 (en) 2021-02-17 2021-03-31 Arecor Ltd Novel composition
WO2023122120A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Compositionsand methods for wound healing
TW202409072A (zh) 2022-05-16 2024-03-01 美商英伊布里克斯公司 用於治療個體的α－１抗胰蛋白酶（ＡＡＴ）缺乏症之方法的重組絲胺酸蛋白酶抑制劑（ｓｅｒｐｉｎ）－Ｆｃ融合蛋白之有效劑量

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
RU2139351C1 (ru) 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000052160A1 (en) 1999-03-01 2000-09-08 Human Genome Sciences, Inc. Human serpin proteins
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
EP1189931B1 (en) 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
AU2050501A (en) 1999-12-01 2001-06-12 Human Genome Sciences, Inc. Four disulfide core domain-containing (fdcd) polynucleotides, polypeptides, and antibodies
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
AU2002212606A1 (en) * 2000-11-08 2002-05-21 Prometic Biosciences Inc Method for the treatment of inflammation
AU2002226897B2 (en) 2000-12-07 2007-10-25 Eli Lilly And Company GLP-1 fusion proteins
JP4336498B2 (ja) * 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
ATE384800T1 (de) * 2000-12-18 2008-02-15 Arriva Pharmaceuticals Inc Multifunktionelle protease-inhibitoren und deren verwendung zur behandlung von krankheiten
US7211395B2 (en) * 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1415664A1 (en) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Use of alpha 1-antichymotrypsin in combination with alpha-1-antitrypsin for treating/preventing diabetes associated or poorly healing arterial wounds
US7427595B1 (en) * 2002-12-12 2008-09-23 Cornell Research Foundation, Inc. Use of proepithelin to promote wound repair and reduce inflammation
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
SI1641483T1 (sl) 2003-06-12 2008-08-31 Lilly Co Eli Fuzijski proteini
WO2005019434A2 (en) * 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
DK2256134T3 (da) * 2003-11-13 2014-02-24 Hanmi Science Co Ltd IgG Fc-fragment til en lægemiddelbærer og fremgangsmåde til fremstilling deraf
AU2005221151A1 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
ES2332100T3 (es) 2004-05-13 2010-01-26 Eli Lilly And Company Proteinas de fusion del fgf-21.
WO2006017647A1 (en) 2004-08-03 2006-02-16 Transtech Pharma, Inc. Rage fusion proteins and methods of use
BRPI0514259A (pt) 2004-08-11 2008-06-03 Trubion Pharmaceuticals Inc proteìna de fusão de domìnio de ligação
US7399746B2 (en) 2004-10-06 2008-07-15 Mcgill University Agents for wound healing
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DK2325207T3 (da) 2004-11-12 2017-06-06 Xencor Inc Fc-varianter med ændret binding til FcRn
ES2971647T3 (es) * 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
ES2523666T3 (es) * 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
US8252905B2 (en) 2005-06-03 2012-08-28 Mochida Pharmaceutical Co., Ltd. Anti-CD14 antibody fusion protein
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US7713521B2 (en) 2005-08-12 2010-05-11 Schering Corporation MCP1 fusions
CN103479994B (zh) * 2005-11-23 2019-08-30 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2012819A2 (en) 2006-03-30 2009-01-14 The Research Foundation Of the City university of New York Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
ZA200900836B (en) 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-fusion proteins
WO2008138017A2 (en) 2007-05-08 2008-11-13 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
JP5577243B2 (ja) * 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション 免疫グロブリン融合タンパク質
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
US8598315B2 (en) * 2007-10-02 2013-12-03 Research Foundation Of City University Of New York Protein transduction domains derived from secretory leukocyte protease inhibitor
AR064713A1 (es) 2007-12-28 2009-04-22 Consejo Nac Invest Cient Tec Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CN102112493B (zh) * 2008-07-23 2015-04-01 韩美科学株式会社 包含具有三个官能性末端的非肽基聚合物的多肽复合物
AU2009279806B2 (en) 2008-08-04 2015-04-30 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
EP2786762B1 (en) 2008-12-19 2019-01-30 MacroGenics, Inc. Covalent diabodies and uses thereof
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
EP2423233B1 (en) * 2009-04-22 2015-03-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
SE533763C2 (sv) 2009-05-04 2010-12-28 Lars Hammar Upphängningsanordning
CN103002727B (zh) 2009-07-08 2016-04-27 密苏里大学管委会 利用传统大豆育种技术培育高油酸大豆的方法
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
GB201003559D0 (en) 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
EP2588140A4 (en) 2010-06-30 2015-07-15 Univ Maryland DENTAL COMPOUNDS WITH NANOPARTICLES OF AMORPHIC CALCIUM PHOSPHATE
BR112013018317A2 (pt) 2010-12-23 2017-03-21 Janssen Biotech Inc mutantes de fc do anticorpo resistentes a protease ativa
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
KR20200044138A (ko) 2011-06-24 2020-04-28 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
KR20140068861A (ko) 2011-06-28 2014-06-09 인히브릭스 엘엘씨 Wap 도메인 융합 폴리펩티드 및 이의 이용 방법
MX356517B (es) 2011-06-28 2018-06-01 Inhibrx Llc Polipéptidos de fusión de serpina y métodos de uso de los mismos.
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
AU2012279205B2 (en) * 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
EP2863954A1 (en) 2012-06-21 2015-04-29 Indiana University Research and Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
CA2871882A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
DK2880170T3 (da) 2012-08-02 2016-10-24 Hoffmann La Roche FREMGANGSMÅDE TIL FREMSTILLING AF OPLØSELIGT FcR SOM Fc-FUSION MED INERT IMMUNOGLOBULIN Fc-REGION OG ANVENDELSER DERAF
US9758807B2 (en) 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides
CN203917563U (zh) 2014-03-27 2014-11-05 陈广煌 一种切角模具
WO2015191892A2 (en) * 2014-06-11 2015-12-17 Beth Israel Deaconess Medical Center, Inc. α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES

Also Published As

Publication number Publication date
US20150147325A1 (en) 2015-05-28
RU2642310C2 (ru) 2018-01-24
IL230209B (en) 2020-08-31
KR20200027041A (ko) 2020-03-11
WO2013003641A2 (en) 2013-01-03
WO2013003641A3 (en) 2013-03-21
CN110551223A (zh) 2019-12-10
RU2017145308A3 (da) 2019-02-18
CA2839619C (en) 2021-11-16
KR102084944B1 (ko) 2020-04-17
ME03473B (me) 2020-01-20
CA3132298A1 (en) 2013-01-03
US20180179264A1 (en) 2018-06-28
US20210024613A1 (en) 2021-01-28
HRP20191652T1 (hr) 2019-12-13
US20200102371A1 (en) 2020-04-02
US11965017B2 (en) 2024-04-23
US20130330769A1 (en) 2013-12-12
EP2726092B1 (en) 2019-06-19
UA124083C2 (uk) 2021-07-21
US20210002352A1 (en) 2021-01-07
AU2019202904A1 (en) 2019-05-16
US10723785B2 (en) 2020-07-28
KR20210032558A (ko) 2021-03-24
IL276534A (en) 2020-09-30
KR20220003656A (ko) 2022-01-10
IL312872A (en) 2024-07-01
AU2012275287B2 (en) 2017-10-05
IN2013MN02441A (da) 2015-06-12
RU2727452C1 (ru) 2020-07-21
US8980266B2 (en) 2015-03-17
AU2017279724A1 (en) 2018-01-25
PL2726092T3 (pl) 2019-11-29
AU2019202904B2 (en) 2021-01-07
AU2017279724B2 (en) 2019-03-14
CN103917563A (zh) 2014-07-09
PT2726092T (pt) 2019-10-08
SI2726092T1 (sl) 2019-11-29
EP2726092A2 (en) 2014-05-07
US11827691B2 (en) 2023-11-28
US10730929B2 (en) 2020-08-04
MX356517B (es) 2018-06-01
LT2726092T (lt) 2019-10-10
JP2018008956A (ja) 2018-01-18
RU2728861C1 (ru) 2020-07-31
HUE046156T2 (hu) 2020-02-28
BR112013033799A2 (pt) 2017-02-14
JP2014523900A (ja) 2014-09-18
SG10201601621PA (en) 2016-04-28
KR20140054000A (ko) 2014-05-08
CN110066340A (zh) 2019-07-30
JP2020078325A (ja) 2020-05-28
CN110066340B (zh) 2024-06-25
AU2012275287A1 (en) 2014-01-16
JP6674604B2 (ja) 2020-04-01
US9920109B2 (en) 2018-03-20
RS59368B1 (sr) 2019-11-29
EP2726092A4 (en) 2015-08-19
NZ744257A (en) 2022-10-28
CY1122195T1 (el) 2020-11-25
AU2021202131A1 (en) 2021-05-06
KR102231139B1 (ko) 2021-03-24
KR20230114318A (ko) 2023-08-01
ES2746052T3 (es) 2020-03-04
RU2020124172A (ru) 2022-01-21
JP2022109968A (ja) 2022-07-28
JP2024138397A (ja) 2024-10-08
CA2839619A1 (en) 2013-01-03
AU2021202131B2 (en) 2023-01-12
MX2013015323A (es) 2014-06-23
RU2017145308A (ru) 2019-02-18
US20130011398A1 (en) 2013-01-10
RU2014102583A (ru) 2015-08-10
SG10201811256QA (en) 2019-01-30
NZ619023A (en) 2015-07-31
RU2698655C2 (ru) 2019-08-28
EP3569243A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
DK2726092T3 (da) Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf
DK2692026T3 (da) Forspændingselement til fastholdelse af kontinuitet og tilknyttet fremgangsmåde
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2785744T3 (da) Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2619576T3 (da) Midler og fremgangsmåder til forudsigelse af behandlingsrespons hos en cancerpatient
DK2950535T3 (da) Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK2552434T3 (da) Peptider og anvendelse deraf
DK2584921T3 (da) Sondeernæringspakninger og fremgangsmåder til anvendelse deraf
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK2758349T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
DK3381461T3 (da) Peptider og fremgangsmåder til anvendelse deraf
DK3199533T3 (da) Pyrazolforbindelse og farmaceutisk anvendelse deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2782598T3 (da) Rekombinante proteiner og terapeutiske anvendelser deraf
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
DK2983704T3 (da) Fusionspolypeptider og vacciner